POPULARITY
10 episodes with socinski
12 episodes with socinski
4 episodes with socinski
7 episodes with socinski
5 episodes with socinski
2 episodes with socinski
3 episodes with socinski
6 episodes with socinski
Drs. Sabari and Socinski discuss maintenance therapy strategies in small cell lung cancer, including immunotherapy, chemotherapy, targeted agents, and radiation.
Drs. Socinski and Sabari discuss a couple of abstracts from ASCO 2025 about emerging therapeutics in small cell lung cancer.
As part of the OncView video series, CancerNetwork spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida about updates in the management of extensive-stage small cell lung cancer (ES-SCLC). Socinski touched on a number of important aspects of treating this disease, including the existing standards of care, treatment challenges, immunotherapy, IMpower 133 trial, and more. Don't forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.
Host: Mark A. Socinski, MD Guest: Alexander Drilon, MD There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice. Since this CME activity has been published the FDA has approved a new treatment for adults with metastatic RET fusion-positive non-small cell lung cancer. To learn more about this approval, please visit the FDA.gov: FDA approves pralsetinib for lung cancer with RET gene fusions
Host: Mark A. Socinski, MD Guest: Alexander Drilon, MD There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice.
Host: Mark A. Socinski, MD Guest: Helena Yu, MD Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.
Host: Mark A. Socinski, MD Guest: Helena Yu, MD Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival. In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.
Host: Mark A. Socinski, MD Guest: Gilberto de Lima Lopes Junior, MD, MBA, FAMS Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.
Host: Mark A. Socinski, MD Guest: Gilberto de Lima Lopes Junior, MD, MBA, FAMS Advanced non-small cell lung cancer (NSCLC) remains incurable; however, advances in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This discussion between Drs. Mark Socinski and Gilberto de Lima Lopes reviews the emerging scientific and clinical data on the role of immunotherapy in mutation-positive NSCLC. Tune in to discover how these therapeutics can benefit your patients.
Host: Mark A. Socinski, MD Guest: Edward B. Garon, MD, MS Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.
Host: Mark A. Socinski, MD Guest: Edward B. Garon, MD, MS Advanced non-small cell lung cancer (NSCLC) remains incurable, but overall survival is improving, as shown by new scientific and clinical data that are emerging on the use of checkpoint inhibitors in the frontline setting and after disease progression. This discussion between Drs. Mark Socinski and Edward Garon addresses the role of PD-L1 expression and reviews how the newer checkpoint inhibitors can be applied to clinical practice.
Host: Mark A. Socinski, MD Guest: Suresh S. Ramalingam, MD While advanced non-small cell lung cancer remains incurable, innovations in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This activity will discuss the new scientific and clinical data that have rapidly emerged on immunotherapies in the frontline setting that are leading to changes in the standard of care. Find out how these newer therapeutics will be utilized in everyday clinical practice.
Host: Mark A. Socinski, MD Guest: Suresh S. Ramalingam, MD While advanced non-small cell lung cancer remains incurable, innovations in treatment and new insights into the molecular pathogenesis of the disease have led to the development of treatments that significantly extend overall survival. This activity will discuss the new scientific and clinical data that have rapidly emerged on immunotherapies in the frontline setting that are leading to changes in the standard of care. Find out how these newer therapeutics will be utilized in everyday clinical practice.
CME credits: 0.25 Valid until: 10-01-2021 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-the-latest-clinical-trials-in-lung-cancer/11161/ In spite of the available evidence supporting the critical need for molecular testing to help determine which treatment is best for patients with non-small cell lung cancer, better strategies are needed to change how and when molecular testing occurs in the diagnostic journey. To help overcome this challenge as well as the challenges related to the initiation and sequencing of treatment with immunotherapies and TKIs in patients with lung cancer, Drs. Mark A. Socinski and Tarek M. Mekhail sit down together to dive into the latest insights from the 2019 ESMO Asia Congress.
CME credits: 0.25 Valid until: 10-01-2021 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-the-latest-clinical-trials-in-lung-cancer/11161/ In spite of the available evidence supporting the critical need for molecular testing to help determine which treatment is best for patients with non-small cell lung cancer, better strategies are needed to change how and when molecular testing occurs in the diagnostic journey. To help overcome this challenge as well as the challenges related to the initiation and sequencing of treatment with immunotherapies and TKIs in patients with lung cancer, Drs. Mark A. Socinski and Tarek M. Mekhail sit down together to dive into the latest insights from the 2019 ESMO Asia Congress.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn't have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
Clinical Investigator and Nursing Perspectives on the Management of Common Cancers. Lung Cancer Edition. Interview with Mark A Socinski, MD conducted by Neil Love, MD. Produced by Research To Practice.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.
Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.
Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Case 1 from the practice of Matthew R Skelton, MD presented to Mark A Socinski, MD. Interview conducted by Neil Love, MD. Produced by Research To Practice.
Case 3 from the practice of Matthew R Skelton, MD presented to Mark A Socinski, MD. Interview conducted by Neil Love, MD. Produced by Research To Practice.
Case 4 from the practice of Matthew R Skelton, MD presented to Mark A Socinski, MD. Interview conducted by Neil Love, MD. Produced by Research To Practice.
Case 2 from the practice of Matthew R Skelton, MD presented to Mark A Socinski, MD. Interview conducted by Neil Love, MD. Produced by Research To Practice.
Case 5 from the practice of Matthew R Skelton, MD presented to Mark A Socinski, MD. Interview conducted by Neil Love, MD. Produced by Research To Practice.
Case 6 from the practice of Matthew R Skelton, MD presented to Mark A Socinski, MD. Interview conducted by Neil Love, MD. Produced by Research To Practice.
ResearchToPractice.com/LCU210 – Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Mark A Socinski, MD conducted by Neil Love, MD. Produced by Research To Practice.
ResearchToPractice.com/LCU309 – Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Mark A Socinski, MD conducted by Neil Love, MD. Produced by Research To Practice.
ResearchToPractice.com/MTP/Lung – Case from the practice of Steven P Kanner, MD presented to Dr Socinski, moderated by Neil Love, MD. Produced by Research To Practice.
ResearchToPractice.com/MTP/Lung – Case from the practice of Charles M Farber, MD, PhD presented to Dr Socinski, moderated by Neil Love, MD. Produced by Research To Practice.
ResearchToPractice.com/MTP/Lung – Case from the practice of Malek Safa, MD presented to Dr Socinski, moderated by Neil Love, MD. Produced by Research To Practice.
LungCancerUpdate.com/Nurses – An Audio Review Journal for Nurses. Interviews conducted by Neil Love, MD. Produced by Research To Practice.
www.LungCancerUpdate.com – Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interviews conducted by Neil Love, MD. Produced by Research To Practice.
Interview with Mark A Socinski, MD
© 2020-2025 Ivy Podcast Discovery LLC
